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Abstract
Blood transfusion is frequent in critical care. Transfusion raises the mass of transfused blood
components and is lifesaving in acute hemorrhage. In massive transfusion (>10 units of red blood
cells), early attempts to restore coagulation function appear helpful. Transfusion in non-bleeding
patients is largely prophylactic, is seldom evidence-based, and may be deleterious. In hemodyna-
mically stable critical care patients, level I evidence suggests that a hemoglobin of >7 g/dL and platelet
counts of >10,000/μL are well tolerated.
Introduction and context
The need for critical care is expanding as society ages.
Patients in intensive care units (ICUs) are highly
transfused, with one-third of ICU patients transfused
and 50% of mechanically ventilated patients receiving at
least one transfusion [1]. The prevalence of transfusion is
lower in injured patients, with 9% of trauma patients
transfused and 2% massively transfused.
Transfusion is safer than ever, with the fraction of
transfused units contaminated with HIV, hepatitis B or C,
syphilis, West Nile virus, or Chagas disease agents at all-
time lows. Transfusion is still complicated by acute and
delayed reactions and by immunosuppressive effects and
association with lung injury.
By raising the mass of transfused blood components,
transfusion can increase oxygen-carrying capacity, pro-
vide substrate for clot formation, and replace plasma
functions as well. Both observational and randomized
clinical trials have sought to balance these benefits
against the pro-inflammatory and immunosuppressive
effects of allogenic transfusion. Transfusion in the
absence of clear need is best avoided as it is wasteful
and potentially dangerous.
There is class I evidence that supports a conservative
transfusion strategy in the critically ill patient. The
Transfusion Requirements in Critical Care (TRICC)
study [2] randomly assigned 838 hemodynamically
stable ICU patients whose hemoglobin (Hb) reached
9 g/dL either to receive transfusions to support them
above an Hb of 10 g/dL or to be transfused only when
their Hb went below 7 g/dL. Outcomes were equivalent
or better with reduced transfusions, even in patients with
cardiovascular disease. For patients with acute coronary
ischemia, no randomized trial to guide the transfusion
threshold exists. On the basis of animal and observa-
tional studies, patients with acute coronary syndromes
should be transfused at a threshold Hb of between 8 and
11 g/dL [3]. There appears to be no benefit (in fact, there
is possible harm) in transfusing at thresholds higher than
these. It is not known whether there is a cerebral
equivalent to acute coronary ischemia, but transfusion
aboveotherbodyrequirementsgenerallyisnotbeneficial
in brain injury. Investigators have explored using packed
red blood cell (RBC) transfusion in multi-modality trials
to increase oxygen delivery in septic shock. Although
two of these studies reported improved survival (while
many have not), this was likely due to other therapies
in the intervention. Multiple well-performed studies
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tion or end-organ perfusion in septic patients after
transfusion.
As is the case for packed RBCs, there is compelling
evidence that supports a conservative platelet transfusion
strategy. Data from nine randomized clinical trials in
acute leukemia and bone marrow transplant patients
show that a threshold of 10,000 platelets/mL is associated
with no more bleeding than higher transfusion triggers
[4]. Prior studies have addressed the platelet count
necessary for bedside procedures. Invasive procedures
can be performed at platelet counts of 40,000/mL,
according to American Society of Clinical Oncology
guidelines [5]. Largely on the basis of consensus, the
American Society of Anesthesiologists recommends
platelet counts of 50,000/mL for general surgery and
100,000/mL for neurosurgery. Good operative technique
is the best protection against excessive bleeding.
Fewer data to guide fresh frozen plasma administration
exist, although it can be inferred that current usage may
be greater than necessary. Non-bleeding patients on
warfarin with international normalized ratios (INRs) of
as high as 8 can be treated by simply holding the
warfarin. Invasive bedside and operative procedures,
with the possible exception of neurosurgery, are gen-
erally safe with prothrombin time (PT) and activated
partial thromboplastin time (PTT) ratios of up to 1.5
times normal, and plasma and fresh frozen plasma
transfusion should not be given without clinical evi-
dence of coagulopathy.
The pathophysiology of the trauma patient differs
markedly from that of the non-hemorrhagic patient.
About a quarter of severely injured trauma patients arrive
at the trauma center coagulopathic as measured by a
prolonged PT. Even those who are normal but actively
bleeding will become coagulopathic after the transfusion
of 6 units of RBCs in the absence of additional plasma.
Treating the coagulopathy of these patients early appears
to improve their outcome. Thus, patients who are
severely injured, actively bleeding, and likely to be
massively transfused appear to benefit from the early
administration of RBCs, plasma, and platelets in a 1:1:1
unit ratio [6]. This should be continued until the rate of
bleeding slows to the point at which continued correc-
tion can be based on laboratory measurements. Several
recent expert panels have suggested that platelet counts
of 100,000/mL are an appropriate goal in severely injured
polytrauma patients. Even with 1:1:1 replacement, it
may be difficult to achieve an Hb of >9, a platelet count
of >90,000/mL, and an INR of <1.5 during massive
transfusion given that components become diluted
during the collection process and suffer loss of potency
during storage and reinfusion.
Recent advances
Our understanding of the acute coagulopathy of trauma
has been expanded by a comparison of admission
coagulation studies with outcome in 35,000 trauma
patients [7]. As injury severity increased, abnormalities of
the PT, PTT, fibrinogen concentration, and platelet count
all became more frequent, and elevations of any of these
indices were associated with increased mortality in a
stepwise manner. Our understanding of the risks and
benefits of aggressive plasma resuscitation in trauma has
been aided by a review of a large prospective study of
inflammatory mediators in trauma patients, which
showed that the greater use of plasma was associated
with a higher rate of lung injury but lower overall
mortality.
Results of the largest randomized trial in transfusion, the
Platelet Dose (PlaDo) trial, have been presented at
international meetings. PlaDo also found that a more
liberal prophylactic platelet replacement strategy was not
associated with improved outcomes, including reduc-
tions in bleeding risk. Additionally, this study validated
the use of a 10,000/mL transfusion trigger as safe.
Although PlaDo found that bleeding among thrombo-
cytopenic patients is common, only one hemorrhage-
related death occurred among the 1,278 patients in this
study.
Recent observational studies have found that transfusion
is associated with the development of acute lung injury
and can also increases the risk of death from it [8]. These
studies have led to a call to expand the definition of
transfusion-related acute lung injury [9] and have
reinforced the need for a conservative transfusion
strategy in non-hemorrhagic patients.
Implications for clinical practice
Evidence for a general approach of avoiding transfusion
as much as possible in patients who are not bleeding and
that of treating massive hemorrhage to abolish coagulo-
pathy have both been strengthened. Neither approach is
as dangerous as its alternative. Clinicians should
continue a conservative packed RBC transfusion strategy,
transfusing 1 unit at a threshold of 7 g/dL in non-
hemorrhagic patients. For patients with coronary syn-
dromes, the target Hb is likely higher. The PlaDo study
upends the historic assumption that the bleeding risk
increases as platelet counts decline in oncology patients.
Given that unnecessary platelet transfusion carries with it
the risk of alloimmunization, transfusion reactions, and
additional cost, it is increasingly difficult for clinicians
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